NC
FULC icon

NewSquare Capital’s Fulcrum Therapeutics FULC Stock Holding History

NewSquare Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30
Closed -$99 – 696
2023
Q2 		$99 Hold
30
– – ﹤0.01% 795
2023
Q1 		$86 Hold
30
– – ﹤0.01% 832
2022
Q4 		$218 Buy
+30
New +$196 ﹤0.01% 724

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

NewSquare Capital's FULC Position: Q3 2023 in Review

NewSquare Capital sold out of Fulcrum Therapeutics (FULC) in Q3 2023, closing a stake of 30 shares — an estimated $99 sold.

NewSquare Capital first reported a position in FULC in Q4 2022 and held it in 3 quarters. The position peaked at $218 in Q4 2022. 81 funds tracked by Wall St. Rank hold FULC as of Q3 2023.

  • NewSquare Capital reported no remaining Fulcrum Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 30 Fulcrum Therapeutics shares in Q3 2023, an estimated $99.
  • NewSquare Capital first reported a position in Fulcrum Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Fulcrum Therapeutics position peaked at $218 in Q4 2022.
  • 81 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.